Abstract: Systems and methods are provided to improve traditional chip processing. Using crossbar computations, the convolution layer can be flattened into vectors, and the vectors can be grouped into a matrix where each row or column is a flattened filter. Each submatrix of the input corresponding to a position of a convolution window is also flattened into a vector. The convolution is computed as the dot product of each input vector and the filter matrix. Using intra-crossbar computations, the unused space of the crossbars is used to store replicas of the filters matrices and the unused space in XIN is used to store more elements of the input. In inter-crossbar computations, the unused crossbars are used to store replicas of the filters matrices and the unused XINs are used to store more elements of the input. Then, the method performs multiple convolution iterations in a single step.

Abstract: The invention described herein proposes that the study of pressure loss in an intelligent completion valve (ICV) is carried out considering both different annular flows and the existence of an axial flow coming from an upstream zone. To study pressure losses in ICVs in detail, the CFD-based methodology (Computational Fluid Dynamics) was adopted, where the geometry of a valve can be well represented by a detailed numerical simulation mesh, which allows high precision results. The invention described herein proves that when more than one completed interval produces simultaneously, a phenomenon that we call fluid confluence occurs, and this is responsible for an additional pressure loss. When there is a confluence of fluids, the pressure loss in the valve depends on both the flow coming from the annulus and the flow coming from upstream zones.

Abstract: Herein described is a modified release coated capsule and a process to obtain that capsule.

Abstract: The present invention relates to the therapeutic uses of compositions containing antibody molecules and functional fragments thereof, e.g antibody molecules and functional fragments capable of binding to tumor necrosis factor alpha (TNF?), in the topical treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.

Abstract: A novel form of tile leveling system is disclosed which is made of a metallic material and used for aligning and leveling tiles as they are laid in floors, walls, countertops, or the like. The device has a locking assembly and a bottom plate combined with a shaft that extends from the bottom plate through the locking assembly so that the locking assembly is movable along the length.

Abstract: The present invention relates to the therapeutic uses of compositions containing antibody molecules and functional fragments thereof, e.g antibody molecules and functional fragments capable of binding to tumor necrosis factor alpha (TNF?), in the topical treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.

Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.

Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.

Abstract: The present invention relates to a modified release coated capsule and a process to obtain that capsule.

Abstract: Herein described is a modified release coated capsule and a process to obtain that capsule.

Abstract: A roof tent closure system designed to facilitate the opening and closing of tent equipment. Both halves of the roof box—front and rear—are equipped with two profiles along the edge and perimeter: the front profile and the rear profile. The front profile is fitted with a locking groove. In turn, the rear profile is fitted with an inward-facing oblique skirt. This oblique skirt, under pressure, slots into the locking groove. A push button is located on the rear profile. Pressing the push button releases the oblique skirt from the locking groove, thereby opening the roof tent.

Abstract: The present invention relates to a modified release coated capsule and a process to obtain that capsule.

Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.

Abstract: Systems and methods for balancing levels of liquid fuel among multiple vehicle-mounted fuel tanks utilize at least one control valve that is configured to admit pressurized gas into a first fuel tank while a second fuel tank is ventilated, responsive to detection of a difference of liquid fuel levels within the first and second fuel tanks. Admission of pressurized gas into one fuel tank and ventilation of another fuel tank creates a pressure imbalance that causes liquid fuel to flow through a balancing line connecting the fuel tanks. Balancing may be performed in a bidirectional manner.

Abstract: Systems and methods for balancing levels of liquid fuel among multiple vehicle-mounted fuel tanks utilize at least one control valve that is configured to admit pressurized gas into a first fuel tank while a second fuel tank is ventilated, responsive to detection of a difference of liquid fuel levels within the first and second fuel tanks. Admission of pressurized gas into one fuel tank and ventilation of another fuel tank creates a pressure imbalance that causes liquid fuel to flow through a balancing line connecting the fuel tanks. Balancing may be performed in a bidirectional manner.

Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.

Abstract: The present invention relates to the therapeutic uses of compositions containing antibody molecules and functional fragments thereof e.g antibody molecules and functional fragments capable of binding to tumor necrosis factor alpha (TNF?), in the topical treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.

Abstract: The present invention relates to a delayed release pharmaceutical formulation for delivering an active agent to the intestine, a method of preparing such formulation and the use of such formulation in the treatment of gastrointestinal disorders.